NBDF/ LinkedIn
Aug 31, 2025, 07:31
Avatrombopag Shows Promise for Pediatric Immune Thrombocytopenia in Late-Stage Global Trial: NBDF
National Bleeding Disorders Foundation shared on LinkedIn:
“Promising news for children and adolescents living with immune thrombocytopenia (ITP). A late-stage global trial shows avatrombopag, an oral treatment already approved for adults, can significantly improve platelet counts and reduce bleeding symptoms in pediatric patients, offering a potential new treatment option for an underserved population.
Learn more about the study results and what they could mean for pediatric ITP care in The Lancet Haematology.”
Stay updated with Hemostasis Today.
-
Mar 12, 2026, 11:05Robert Lufkin: One Minute of Wisdom from Robert Lustig on Cholesterol, Sugar, and Heart Disease
-
Mar 12, 2026, 10:36Cynthia Dunbar: Retiring From NIH After 39 Years to Advance Advocacy and Research in Hematology
-
Mar 11, 2026, 23:05Ney Carter Borges: A Safety Advantage of Apixaban over Rivaroxaban Without Clear Superiority
-
Mar 11, 2026, 22:01The Results of Landmark COBRRA Trial in Acute VTE Management – ISTH
-
Mar 11, 2026, 21:19Peter Antevy: EMS Rarely Suspects Pediatric Stroke And It’s Costing Kids Time
-
Mar 11, 2026, 19:24Robert Sidonio: Prophylaxis with Wilate and The WIL-31 Study Results
-
Mar 11, 2026, 18:42Annette Logan-Parker: A Hemophilia B Breakthrough – From Weekly Infusions to One Treatment
-
Mar 11, 2026, 18:27Cesar Garrido and Lackram Bodoe Are Advancing WFH Partnerships in Trinidad and Tobago
-
Mar 11, 2026, 18:14Aloke Finn: Silent Plaque Rupture and Healing in Coronary Artery Disease